Unregulated Kratom: A Public Health Time Bomb

Poison center calls about kratom have surged more than 1,200% in a decade, signaling a public health crisis that medical professionals say is being ignored by regulators and consumers alike.

Quick Take

Kratom exposure reports jumped from 258 in 2015 to a record 3,434 in 2025, with hospitalizations climbing over 1,150% during the same period.
Two hundred thirty-three deaths were linked to kratom use between 2015 and 2025, with 184 involving multiple substances.
The herb remains unregulated federally despite growing availability in vape shops and gas stations, creating a perfect storm of potency and accessibility.
When mixed with alcohol, medications, or illicit drugs, 60% of cases in 2025 resulted in serious medical outcomes requiring hospitalization.
Men in their 20s and 30s represent most cases, but alarming increases now appear among adults aged 40 to 59.

The Quiet Explosion Nobody Saw Coming

For years, kratom occupied the gray space between health food and controlled substance. The Southeast Asian plant arrived in American vape shops and gas stations with minimal fanfare, marketed as a natural pain reliever and opioid alternative. Few consumers questioned what they were buying. Fewer still understood the chemical complexity of what they were ingesting. That complacency ended abruptly when poison centers across the nation began drowning in calls.

The numbers tell a story of exponential danger. Between 2015 and 2025, calls to poison centers increased by more than 1,200%, with 2025 alone accounting for 3,434 reports compared to just 258 a decade earlier. These aren’t minor incidents. Hospitalizations involving kratom alone surged over 1,150% from 43 cases in 2015 to 538 in 2025. When users combined kratom with other substances—alcohol, prescription medications, illicit drugs—hospitalizations climbed nearly 1,300%, from 40 to 549.

The trajectory reveals a pattern that should alarm anyone paying attention. Researchers found steady increases from 2015 through 2019, followed by a plateau from 2020 to 2024, then a sharp, unprecedented surge in 2025. This wasn’t gradual drift. This was acceleration. During the entire decade, over 14,400 kratom exposures were reported to the National Poison Data System. Of the 233 deaths linked to kratom use during this period, 184 involved multiple substances—a detail that complicates the narrative but doesn’t diminish the severity.

Who’s Actually Using This Stuff

The demographics paint a picture of expanding vulnerability. Initially, kratom use concentrated among men in their 20s and 30s seeking alternatives to opioids or looking for a legal high. That profile has shifted dramatically. Reports among adults aged 40 to 59 have increased sharply, suggesting the substance has penetrated deeper into mainstream consciousness than anyone anticipated. This age expansion matters because older users often take multiple medications, creating dangerous interaction scenarios.

The chemical complexity underlying kratom’s appeal is precisely what makes it dangerous. The plant contains mitragynine and 7-hydroxymitragynine—alkaloids with complex pharmacological actions that vary wildly depending on product formulation, concentration, and preparation method. Unregulated manufacturers have responded to demand by producing increasingly potent versions. There’s no standardization, no quality control, no way for consumers to know what concentration they’re getting or how it will interact with their existing medications or substances.

The Regulatory Vacuum That Enables Chaos

Kratom remains unscheduled at the federal level, a regulatory gap that has allowed the market to flourish unchecked. Some states have moved to restrict or ban it entirely, but progress stalls amid litigation and advocacy from kratom users who argue the substance saved them from opioid addiction. The American Kratom Association lobbies aggressively against restrictions, framing regulation as government overreach. Meanwhile, the FDA issues import alerts addressing high volumes of kratom-containing products entering the United States, but these measures arrive too late to prevent widespread distribution.

Medical professionals are sounding alarms that policy makers appear unwilling to hear. Dr. Chris Holstege, director of UVA Health’s Blue Ridge Poison Center, emphasized that kratom products contain chemicals of varying concentrations capable of causing drug interactions and serious adverse consequences. In 2025, when 60% of multi-substance exposure reports resulted in serious medical outcomes, the data validated what emergency room physicians already knew: this problem was accelerating beyond their capacity to manage it effectively.

The gap between consumer perception and medical reality has become a chasm. Users believe they’re consuming a natural, safe supplement. Doctors see seizures, hallucinations, vomiting, elevated blood pressure, and organ damage. This disconnect persists because kratom occupies a legal twilight zone where it can be sold openly but not regulated like pharmaceuticals. The result is a market driven entirely by profit incentives, with no mandatory safety standards, potency limits, or contamination testing.

What Comes Next

The 2025 surge suggests we’re witnessing the early stages of a crisis that will demand attention whether regulators choose to provide it or not. Emergency departments will fill with kratom-related cases. Poison centers will continue fielding calls. Deaths will mount. The question isn’t whether action will eventually be taken—it’s whether that action will come proactively through sensible regulation or reactively through crisis management after preventable harm has already occurred. The trajectory is clear. The time for decisive policy response is now.